| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC35D2 |
| Uniprot No | Q76EJ3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-249 aa |
| 活性数据 | MTAGGQAEAEGAGGEPGAARLPSRVARLLSALFYGTCSFLIVLVNKALLTTYGFPSPIFLGIGQMAATIMILYVSKLNKIIHFPDFDKKIPVKLFPLPLLYVGNHISGLSSTSKLSLPMFTVLRKFTIPLTLLLETIILGKQYSLNIILSVFAIILGAFIAAGFLLMYSTVLCSYYNSALTTAVVGAIKNVSVAYIGILIGGDYIFSLLNFVGLNICMAGGLRYSFLTLSSQLKPKPVGEENICLDLKS |
| 分子量 | 53.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC35D2蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Functional characterization of recombinant human SLC35D2 as a nucleotide sugar transporter in the Golgi apparatus"*
**作者**：Zhang L. et al.
**摘要**：本研究通过重组表达人SLC35D2蛋白于HEK293细胞，证实其作为UDP-葡萄糖醛酸(UDP-glucuronic acid)的特异性转运体，定位在高尔基体膜。实验表明，SLC35D2的转运活性依赖酸性pH环境，并参与糖胺聚糖的生物合成。
2. **文献名称**：*"Cryo-EM structure of human SLC35D2 reveals mechanisms of substrate recognition and transport"*
**作者**：Tanaka K. et al.
**摘要**：作者利用重组SLC35D2蛋白进行冷冻电镜结构解析，首次揭示了其三维构象及底物结合口袋的关键氨基酸残基。该研究为设计靶向SLC35D2的小分子药物提供了结构基础。
3. **文献名称**：*"SLC35D2 deficiency disrupts glycosylation and promotes epithelial-mesenchymal transition in cancer cells"*
**作者**：Liu Y. et al.
**摘要**：通过shRNA敲低和重组蛋白回补实验，本文发现SLC35D2缺失导致结肠癌细胞中E-cadherin糖基化异常，从而增强细胞迁移和转移能力，提示其在癌症进展中的潜在作用。
4. **文献名称**：*"A high-throughput assay for SLC35D2 transporter activity using recombinant protein in liposomes"*
**作者**：Patel R. et al.
**摘要**：开发了一种基于脂质体重组SLC35D2蛋白的高通量检测方法，定量分析其转运活性，并筛选出多个小分子抑制剂，为疾病治疗提供新策略。
**注**：以上文献为模拟示例，实际引用需以真实发表的研究为准。
Recombinant human SLC35D2 (Solute Carrier Family 35 Member D2) is a transmembrane protein belonging to the nucleotide-sugar transporter (NST) family. Located primarily in the Golgi apparatus and endoplasmic reticulum, SLC35D2 facilitates the transport of nucleotide-activated sugars, such as UDP-glucuronic acid and UDP-N-acetylgalactosamine, into these organelles. This process is critical for glycosylation, a post-translational modification essential for protein folding, stability, and cellular recognition. SLC35D2's activity influences the biosynthesis of glycoproteins, proteoglycans, and glycolipids, which are vital for cell-cell communication, immune responses, and tissue development.
The SLC35D2 gene is mapped to human chromosome 3p21.31 and has been linked to developmental disorders and metabolic diseases. Mutations in SLC35D2 are associated with Schneckenbecken dysplasia, a lethal skeletal dysplasia caused by defective glycosaminoglycan synthesis. Additionally, altered SLC35D2 expression has been observed in cancers, suggesting potential roles in tumor progression and metastasis.
Recombinant SLC35D2 is produced using heterologous expression systems (e.g., mammalian or insect cells) to study its structure, transport mechanisms, and interactions. Its recombinant form enables biochemical assays, drug screening, and functional studies aimed at elucidating its role in glycosylation-related pathologies. Research on this protein may contribute to therapies targeting glycosylation defects or cancer metabolism.
×
